Last reviewed · How we verify

Intra-articular Compound Betamethasone

Chinese PLA General Hospital · FDA-approved active Small molecule

Betamethasone is a corticosteroid that suppresses local inflammatory and immune responses when injected directly into a joint.

Betamethasone is a corticosteroid that suppresses local inflammatory and immune responses when injected directly into a joint. Used for Intra-articular inflammation and pain in rheumatoid arthritis, Osteoarthritis joint inflammation, Other inflammatory joint conditions.

At a glance

Generic nameIntra-articular Compound Betamethasone
SponsorChinese PLA General Hospital
Drug classCorticosteroid
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaRheumatology / Orthopedics
PhaseFDA-approved

Mechanism of action

Betamethasone binds to glucocorticoid receptors in synovial tissue and immune cells, reducing production of pro-inflammatory cytokines, inhibiting leukocyte infiltration, and decreasing synovial inflammation. Intra-articular administration delivers the drug locally to the affected joint, minimizing systemic exposure while providing anti-inflammatory and immunosuppressive effects that reduce pain and swelling.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: